Aldeyra Therapeutics
ALDX
7 hedge funds and large institutions have $5.64M invested in Aldeyra Therapeutics in 2014 Q2 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.61M |
| 2 |
EEG
E.E. Geduld
|
+$107K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.23K |
| 4 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$1.81K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$470 |
Top Sellers
ALDX Hedge Fund Activity: Q2 2014 in Review
7 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q2 2014, worth a combined $5.64M.
Buyers outnumbered sellers: 7 funds opened new ALDX positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $5.61M.
- 7 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2014, up from 0 in Q1 2014.
- Funds reported $5.64M of Aldeyra Therapeutics stock for Q2 2014.
- 7 funds opened new Aldeyra Therapeutics positions in Q2 2014 and 0 closed out, a net change of +7 holders.
- The largest Aldeyra Therapeutics buyer in Q2 2014 was Fidelity Investments, an estimated $5.61M added.
Based on aggregated 13F filings for Q2 2014.